Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.

J. E. Oesterling, M. F. el Etreby, G. J. Gormley, J. L. Imperato-McGinley, Claus Roehrborn, F. H. Schröder, U. W. Tunn

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In 1993, medical therapy for BPH is a reality. Androgen deprivation therapy (LHRH agonists, antiandrogens, and 5 alpha-reductase inhibitors) has been shown to be effective by reducing the static component of BPH. Of these agents, the 5 alpha-reductase inhibitors have the greatest promise because of their low toxicity profile. Aromatase inhibitors, which function via a different mechanism, however, have not been demonstrated, as monotherapy, to be effective in the treatment of symptomatic BPH. It is still theoretically possible that aromatase inhibitors could have a role in the management of prostatism if they are utilized in conjunction with an antiandrogen or 5 alpha-reductase inhibitor. Although the early results for this endocrine therapies are encouraging, several issues relating to medical treatment remain unanswered. Not everyone with significant prostatism will respond to androgen deprivation therapy. How does the physician identify pre-treatment the patient most likely to achieve a significant improvement in voiding function with 5 alpha-reductase inhibitor therapy? At the present time, there is no method--based on symptoms, DRE findings, serum hormone and PSA levels, or histopathologic criteria--for recognizing the ideal patient for androgen deprivation therapy. Without question, it is a subjective decision. As a result, the benefits and risks of these medical approaches as well as those of the minimally invasive and surgical therapies must be discussed with the patient so that he can participate in the management decision. In this manner, the expectations and needs of the patient will be best served.

Original languageEnglish (US)
Pages (from-to)231-250
Number of pages20
JournalProgress in Clinical and Biological Research
Volume386
StatePublished - 1994

Fingerprint

Patient Selection
5-alpha Reductase Inhibitors
Prostatism
Androgens
Therapeutics
Androgen Antagonists
Aromatase Inhibitors
Gonadotropin-Releasing Hormone
Hormones
Physicians
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Oesterling, J. E., el Etreby, M. F., Gormley, G. J., Imperato-McGinley, J. L., Roehrborn, C., Schröder, F. H., & Tunn, U. W. (1994). Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection. Progress in Clinical and Biological Research, 386, 231-250.

Endocrine therapies for BPH : scientific rationale, clinical results, and patient selection. / Oesterling, J. E.; el Etreby, M. F.; Gormley, G. J.; Imperato-McGinley, J. L.; Roehrborn, Claus; Schröder, F. H.; Tunn, U. W.

In: Progress in Clinical and Biological Research, Vol. 386, 1994, p. 231-250.

Research output: Contribution to journalArticle

Oesterling, JE, el Etreby, MF, Gormley, GJ, Imperato-McGinley, JL, Roehrborn, C, Schröder, FH & Tunn, UW 1994, 'Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.', Progress in Clinical and Biological Research, vol. 386, pp. 231-250.
Oesterling JE, el Etreby MF, Gormley GJ, Imperato-McGinley JL, Roehrborn C, Schröder FH et al. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection. Progress in Clinical and Biological Research. 1994;386:231-250.
Oesterling, J. E. ; el Etreby, M. F. ; Gormley, G. J. ; Imperato-McGinley, J. L. ; Roehrborn, Claus ; Schröder, F. H. ; Tunn, U. W. / Endocrine therapies for BPH : scientific rationale, clinical results, and patient selection. In: Progress in Clinical and Biological Research. 1994 ; Vol. 386. pp. 231-250.
@article{8a342efac8124682b3dcac922cc2084e,
title = "Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.",
abstract = "In 1993, medical therapy for BPH is a reality. Androgen deprivation therapy (LHRH agonists, antiandrogens, and 5 alpha-reductase inhibitors) has been shown to be effective by reducing the static component of BPH. Of these agents, the 5 alpha-reductase inhibitors have the greatest promise because of their low toxicity profile. Aromatase inhibitors, which function via a different mechanism, however, have not been demonstrated, as monotherapy, to be effective in the treatment of symptomatic BPH. It is still theoretically possible that aromatase inhibitors could have a role in the management of prostatism if they are utilized in conjunction with an antiandrogen or 5 alpha-reductase inhibitor. Although the early results for this endocrine therapies are encouraging, several issues relating to medical treatment remain unanswered. Not everyone with significant prostatism will respond to androgen deprivation therapy. How does the physician identify pre-treatment the patient most likely to achieve a significant improvement in voiding function with 5 alpha-reductase inhibitor therapy? At the present time, there is no method--based on symptoms, DRE findings, serum hormone and PSA levels, or histopathologic criteria--for recognizing the ideal patient for androgen deprivation therapy. Without question, it is a subjective decision. As a result, the benefits and risks of these medical approaches as well as those of the minimally invasive and surgical therapies must be discussed with the patient so that he can participate in the management decision. In this manner, the expectations and needs of the patient will be best served.",
author = "Oesterling, {J. E.} and {el Etreby}, {M. F.} and Gormley, {G. J.} and Imperato-McGinley, {J. L.} and Claus Roehrborn and Schr{\"o}der, {F. H.} and Tunn, {U. W.}",
year = "1994",
language = "English (US)",
volume = "386",
pages = "231--250",
journal = "Progress in Clinical and Biological Research",
issn = "0361-7742",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Endocrine therapies for BPH

T2 - scientific rationale, clinical results, and patient selection.

AU - Oesterling, J. E.

AU - el Etreby, M. F.

AU - Gormley, G. J.

AU - Imperato-McGinley, J. L.

AU - Roehrborn, Claus

AU - Schröder, F. H.

AU - Tunn, U. W.

PY - 1994

Y1 - 1994

N2 - In 1993, medical therapy for BPH is a reality. Androgen deprivation therapy (LHRH agonists, antiandrogens, and 5 alpha-reductase inhibitors) has been shown to be effective by reducing the static component of BPH. Of these agents, the 5 alpha-reductase inhibitors have the greatest promise because of their low toxicity profile. Aromatase inhibitors, which function via a different mechanism, however, have not been demonstrated, as monotherapy, to be effective in the treatment of symptomatic BPH. It is still theoretically possible that aromatase inhibitors could have a role in the management of prostatism if they are utilized in conjunction with an antiandrogen or 5 alpha-reductase inhibitor. Although the early results for this endocrine therapies are encouraging, several issues relating to medical treatment remain unanswered. Not everyone with significant prostatism will respond to androgen deprivation therapy. How does the physician identify pre-treatment the patient most likely to achieve a significant improvement in voiding function with 5 alpha-reductase inhibitor therapy? At the present time, there is no method--based on symptoms, DRE findings, serum hormone and PSA levels, or histopathologic criteria--for recognizing the ideal patient for androgen deprivation therapy. Without question, it is a subjective decision. As a result, the benefits and risks of these medical approaches as well as those of the minimally invasive and surgical therapies must be discussed with the patient so that he can participate in the management decision. In this manner, the expectations and needs of the patient will be best served.

AB - In 1993, medical therapy for BPH is a reality. Androgen deprivation therapy (LHRH agonists, antiandrogens, and 5 alpha-reductase inhibitors) has been shown to be effective by reducing the static component of BPH. Of these agents, the 5 alpha-reductase inhibitors have the greatest promise because of their low toxicity profile. Aromatase inhibitors, which function via a different mechanism, however, have not been demonstrated, as monotherapy, to be effective in the treatment of symptomatic BPH. It is still theoretically possible that aromatase inhibitors could have a role in the management of prostatism if they are utilized in conjunction with an antiandrogen or 5 alpha-reductase inhibitor. Although the early results for this endocrine therapies are encouraging, several issues relating to medical treatment remain unanswered. Not everyone with significant prostatism will respond to androgen deprivation therapy. How does the physician identify pre-treatment the patient most likely to achieve a significant improvement in voiding function with 5 alpha-reductase inhibitor therapy? At the present time, there is no method--based on symptoms, DRE findings, serum hormone and PSA levels, or histopathologic criteria--for recognizing the ideal patient for androgen deprivation therapy. Without question, it is a subjective decision. As a result, the benefits and risks of these medical approaches as well as those of the minimally invasive and surgical therapies must be discussed with the patient so that he can participate in the management decision. In this manner, the expectations and needs of the patient will be best served.

UR - http://www.scopus.com/inward/record.url?scp=0028713383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028713383&partnerID=8YFLogxK

M3 - Article

C2 - 7528391

AN - SCOPUS:0028713383

VL - 386

SP - 231

EP - 250

JO - Progress in Clinical and Biological Research

JF - Progress in Clinical and Biological Research

SN - 0361-7742

ER -